SpringerLink
Log in

The expanding role of radiation oncology across the prostate cancer continuum

  • Special Section: Prostate Cancer Update
  • Published:
Abdominal Radiology Aims and scope Submit manuscript

Abstract

Radiotherapy is used in the treatment of prostate cancer in a variety of disease states with significant reliance on imaging to guide clinical decision-making and radiation delivery. In the definitive setting, the choice of radiotherapy treatment modality, dose, and fractionation for localized prostate cancer is determined by the patient’s initial risk stratification and other clinical considerations. Radiation is also an option as salvage therapy in patients with locoregionally recurrent disease after prior definitive radiation or surgery. In recent years, the role of radiation has expanded for patients with metastatic disease, including prostate-directed radiotherapy in de novo low volume metastatic disease, metastasis-directed therapy for oligorecurrent disease, and palliative management of symptomatic metastases in the advanced setting. Here we review the expanding role of radiation in the treatment of prostate cancer in the definitive, locoregionally recurrent, and metastatic settings, as well as highlight the role of imaging in clinical reasoning, radiation planning, and treatment delivery.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. Siegel, Rebecca L., et al. “Cancer Statistics, 2023.” CA: A Cancer Journal for Clinicians, vol. 73, no. 1, 2023, pp. 17–48, https://doi.org/10.3322/caac.21763.

    Article  PubMed  Google Scholar 

  2. Tepper, Joel E., et al., editors. Gunderson & Tepper’s Clinical Radiation Oncology. 5th ed., Elsevier, 2020.

    Google Scholar 

  3. Eng, Tony Y., et al. “The Efficacy of Conventional External Beam, Three-Dimensional Conformal, Intensity-Modulated, Particle Beam Radiation, and Brachytherapy for Localized Prostate Cancer.” Current Urology Reports, vol. 6, no. 3, May 2005, pp. 194–209, https://doi.org/10.1007/s11934-005-0008-3.

    Article  PubMed  Google Scholar 

  4. Ling, C. C., et al. “Conformal Radiation Treatment of Prostate Cancer Using Inversely-Planned Intensity-Modulated Photon Beams Produced with Dynamic Multileaf Collimation.” International Journal of Radiation Oncology, Biology, Physics, vol. 35, no. 4, July 1996, pp. 721–30, https://doi.org/10.1016/0360-3016(96)00174-5.

    Article  CAS  PubMed  Google Scholar 

  5. Zelefsky, Michael J., et al. “Incidence of Late Rectal and Urinary Toxicities after Three-Dimensional Conformal Radiotherapy and Intensity-Modulated Radiotherapy for Localized Prostate Cancer.” International Journal of Radiation Oncology, Biology, Physics, vol. 70, no. 4, Mar. 2008, pp. 1124–29, https://doi.org/10.1016/j.ijrobp.2007.11.044.

    Article  PubMed  Google Scholar 

  6. Goenka, Anuj, et al. “Improved Toxicity Profile Following High-Dose Postprostatectomy Salvage Radiation Therapy with Intensity-Modulated Radiation Therapy.” European Urology, vol. 60, no. 6, Dec. 2011, pp. 1142–48, https://doi.org/10.1016/j.eururo.2011.08.006.

    Article  Google Scholar 

  7. Mariados, Neil, et al. “Hydrogel Spacer Prospective Multicenter Randomized Controlled Pivotal Trial: Dosimetric and Clinical Effects of Perirectal Spacer Application in Men Undergoing Prostate Image Guided Intensity Modulated Radiation Therapy.” International Journal of Radiation Oncology, Biology, Physics, vol. 92, no. 5, Aug. 2015, pp. 971–77, https://doi.org/10.1016/j.ijrobp.2015.04.030.

    Article  Google Scholar 

  8. Ladbury, Colton, et al. “Clinical Applications of Magnetic Resonance-Guided Radiotherapy: A Narrative Review.” Cancers, vol. 15, no. 11, May 2023, p. 2916, https://doi.org/10.3390/cancers15112916.

    Article  Google Scholar 

  9. Kishan, Amar U., et al. “Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial.” JAMA Oncology, vol. 9, no. 3, Mar. 2023, pp. 365–73, https://doi.org/10.1001/jamaoncol.2022.6558.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Wisdom, A. J., et al. “Prostate Advanced Radiation Technologies Investigating Quality of Life (PARTIQoL): A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer.” International Journal of Radiation Oncology Biology Physics, vol. 117, no. 2, 2023, p. e450, https://doi.org/10.1016/j.ijrobp.2023.06.1635.

    Article  Google Scholar 

  11. Bryant, Curtis M., et al. “Consensus Statement on Proton Therapy for Prostate Cancer.” International Journal of Particle Therapy, vol. 8, no. 2, 2021, pp. 1–16, https://doi.org/10.14338/IJPT-20-00031.1.

    Article  PubMed  PubMed Central  Google Scholar 

  12. NCCN. National Comprehensive Cancer Network: Prostate Cancer (Version 3.2024). 2024. Available online: https://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed on 13 March 2024.

  13. Eastham, James A., et al. “Clinically Localized Prostate Cancer: AUA/ASTRO Guideline. Part III: Principles of Radiation and Future Directions.” Journal of Urology, vol. 208, no. 1, 2022, pp. 26–33, https://doi.org/10.1097/JU.0000000000002759.

    Article  PubMed  Google Scholar 

  14. Zietman, Anthony L., et al. “Randomized Trial Comparing Conventional-Dose with High-Dose Conformal Radiation Therapy in Early-Stage Adenocarcinoma of the Prostate: Long-Term Results from Proton Radiation Oncology Group/American College of Radiology 95-09.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 28, no. 7, Mar. 2010, pp. 1106–11, https://doi.org/10.1200/JCO.2009.25.8475.

    Article  PubMed  Google Scholar 

  15. Hennequin, Christophe, et al. “Long-Term Results of Dose Escalation (80 vs 70 Gy) Combined with Long-Term Androgen Deprivation in High-Risk Prostate Cancers: GETUG-AFU 18 Randomized Trial.” Journal of Clinical Oncology, vol. 42, no. 4_suppl, Feb. 2024, pp. LBA259–LBA259, https://doi.org/10.1200/JCO.2024.42.4_suppl.LBA259.

    Article  Google Scholar 

  16. Al-Mamgani, Abrahim, et al. “Dose Escalation and Quality of Life in Patients with Localized Prostate Cancer Treated with Radiotherapy: Long-Term Results of the Dutch Randomized Dose-Escalation Trial (CKTO 96-10 Trial).” International Journal of Radiation Oncology, Biology, Physics, vol. 79, no. 4, Mar. 2011, pp. 1004–12, https://doi.org/10.1016/j.ijrobp.2009.12.039.

    Article  Google Scholar 

  17. Kuban, Deborah A., et al. “Long-Term Results of the M. D. Anderson Randomized Dose-Escalation Trial for Prostate Cancer.” International Journal of Radiation Oncology, Biology, Physics, vol. 70, no. 1, Jan. 2008, pp. 67–74, https://doi.org/10.1016/j.ijrobp.2007.06.054.

    Article  PubMed  Google Scholar 

  18. Morgan, Scott C., et al. “Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline.” Practical Radiation Oncology, vol. 8, no. 6, 2018, pp. 354–60, https://doi.org/10.1016/j.prro.2018.08.002.

    Article  PubMed  Google Scholar 

  19. Hoffman, Karen E., et al. “Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer.” Journal of Clinical Oncology, vol. 36, no. 29, Oct. 2018, pp. 2943–49, https://doi.org/10.1200/JCO.2018.77.9868.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Avkshtol, Vladimir, et al. “Ten-Year Update of a Randomized, Prospective Trial of Conventional Fractionated Versus Moderate Hypofractionated Radiation Therapy for Localized Prostate Cancer.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 38, no. 15, May 2020, pp. 1676–84, https://doi.org/10.1200/JCO.19.01485.

    Article  Google Scholar 

  21. Lee, W. Robert, et al. “Randomized Phase III Noninferiority Study Comparing Two Radiotherapy Fractionation Schedules in Patients With Low-Risk Prostate Cancer.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 34, no. 20, July 2016, pp. 2325–32, https://doi.org/10.1200/JCO.2016.67.0448.

    Article  Google Scholar 

  22. Dearnaley, David, et al. “Conventional versus Hypofractionated High-Dose Intensity-Modulated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the Randomised, Non-Inferiority, Phase 3 CHHiP Trial.” The Lancet Oncology, vol. 17, no. 8, 2016, pp. 1047–60, https://doi.org/10.1016/S1470-2045(16)30102-4.

    Article  Google Scholar 

  23. Wortel, Ruud C., et al. “Moderate Hypofractionation in Intermediate- and High-Risk, Localized Prostate Cancer: Health-Related Quality of Life From the Randomized, Phase 3 HYPRO Trial.” International Journal of Radiation Oncology Biology Physics, vol. 103, no. 4, 2019, pp. 823–33, https://doi.org/10.1016/j.ijrobp.2018.11.020.

    Article  PubMed  Google Scholar 

  24. Ritter, Mark A., et al. “A Prospective Multi-Institutional Phase I/II Trial of Step-Wise Dose-per-Fraction Escalation in Low and Intermediate Risk Prostate Cancer.” Practical Radiation Oncology, vol. 10, no. 5, 2020, pp. 345–53, https://doi.org/10.1016/j.prro.2020.02.013.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Incrocci, Luca, et al. “Hypofractionated versus Conventionally Fractionated Radiotherapy for Patients with Localised Prostate Cancer (HYPRO): Final Efficacy Results from a Randomised, Multicentre, Open-Label, Phase 3 Trial.” The Lancet Oncology, vol. 17, no. 8, 2016, pp. 1061–69, https://doi.org/10.1016/S1470-2045(16)30070-5.

    Article  Google Scholar 

  26. Widmark, Anders, et al. “Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Prostate Cancer: 5-Year Outcomes of the HYPO-RT-PC Randomised, Non-Inferiority, Phase 3 Trial.” The Lancet, vol. 394, no. 10196, 2019, pp. 385–95, https://doi.org/10.1016/S0140-6736(19)31131-6.

    Article  Google Scholar 

  27. Jackson, William C., et al. “Stereotactic Body Radiation Therapy for Localized Prostate Cancer: A Systematic Review and Meta-Analysis of Over 6,000 Patients Treated On Prospective Studies.” International Journal of Radiation Oncology, Biology, Physics, vol. 104, no. 4, July 2019, pp. 778–89, https://doi.org/10.1016/j.ijrobp.2019.03.051.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Brand, Douglas H., et al. “Intensity-Modulated Fractionated Radiotherapy versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-B): Acute Toxicity Findings from an International, Randomised, Open-Label, Phase 3, Non-Inferiority Trial.” The Lancet Oncology, vol. 20, no. 11, 2019, pp. 1531–43, https://doi.org/10.1016/S1470-2045(19)30569-8.

    Article  PubMed  PubMed Central  Google Scholar 

  29. van Dams, Ritchell, et al. “Stereotactic Body Radiotherapy for High-Risk Localized Carcinoma of the Prostate (SHARP) Consortium: Analysis of 344 Prospectively Treated Patients.” International Journal of Radiation Oncology, Biology, Physics, vol. 110, no. 3, July 2021, pp. 731–37, https://doi.org/10.1016/j.ijrobp.2021.01.016.

    Article  Google Scholar 

  30. Tree, Alison C., et al. “Intensity-Modulated Radiotherapy versus Stereotactic Body Radiotherapy for Prostate Cancer (PACE-B): 2-Year Toxicity Results from an Open-Label, Randomised, Phase 3, Non-Inferiority Trial.” The Lancet Oncology, vol. 23, no. 10, 2022, pp. 1308–20, https://doi.org/10.1016/S1470-2045(22)00517-4.

    Article  PubMed  Google Scholar 

  31. Van As, N., et al. “5-Year Outcomes from PACE B: An International Phase III Randomized Controlled Trial Comparing Stereotactic Body Radiotherapy (SBRT) vs. Conventionally Fractionated or Moderately Hypo Fractionated External Beam Radiotherapy for Localized Prostate Cancer.” International Journal of Radiation Oncology Biology Physics, vol. 117, no. 4, 2023, pp. e2–3, https://doi.org/10.1016/j.ijrobp.2023.08.027.

    Article  Google Scholar 

  32. Dearnaley, David P., et al. “Escalated-Dose versus Control-Dose Conformal Radiotherapy for Prostate Cancer: Long-Term Results from the MRC RT01 Randomised Controlled Trial.” The Lancet Oncology, vol. 15, no. 4, 2014, pp. 464–73, https://doi.org/10.1016/S1470-2045(14)70040-3.

    Article  PubMed  Google Scholar 

  33. Michalski, Jeff M., et al. “Effect of Standard vs Dose-Escalated Radiation Therapy for Patients With Intermediate-Risk Prostate Cancer: The NRG Oncology RTOG 0126 Randomized Clinical Trial.” JAMA Oncology, vol. 4, no. 6, June 2018, p. e180039, https://doi.org/10.1001/jamaoncol.2018.0039.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Zaorsky, Nicholas G., et al. “Impact of Radiation Therapy Dose Escalation on Prostate Cancer Outcomes and Toxicities.” American Journal of Clinical Oncology, vol. 41, no. 4, 2018, pp. 409–15, https://doi.org/10.1097/COC.0000000000000285.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Arrayeh, Elnasif, et al. “Does Local Recurrence of Prostate Cancer after Radiation Therapy Occur at the Site of Primary Tumor? Results of a Longitudinal MRI and MRSI Study.” International Journal of Radiation Oncology, Biology, Physics, vol. 82, no. 5, Apr. 2012, pp. e787–793, https://doi.org/10.1016/j.ijrobp.2011.11.030.

    Article  Google Scholar 

  36. Cellini, Numa, et al. “Analysis of Intraprostatic Failures in Patients Treated with Hormonal Therapy and Radiotherapy: Implications for Conformal Therapy Planning.” International Journal of Radiation Oncology Biology Physics, vol. 53, no. 3, 2002, pp. 595–99, https://doi.org/10.1016/S0360-3016(02)02795-5.

    Article  Google Scholar 

  37. Kerkmeijer, Linda G. W., et al. “Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial.” Journal of Clinical Oncology, vol. 39, no. 7, Mar. 2021, pp. 787–96, https://doi.org/10.1200/JCO.20.02873.

    Article  CAS  PubMed  Google Scholar 

  38. Tree, Alison C., et al. “Standard and Hypofractionated Dose Escalation to Intraprostatic Tumor Nodules in Localized Prostate Cancer: 5-Year Efficacy and Toxicity in the DELINEATE Trial.” International Journal of Radiation Oncology Biology Physics, vol. 115, no. 2, 2023, pp. 305–16, https://doi.org/10.1016/j.ijrobp.2022.09.058.

    Article  PubMed  Google Scholar 

  39. Chargari, Cyrus, et al. “Brachytherapy: An Overview for Clinicians.” CA: A Cancer Journal for Clinicians, vol. 69, no. 5, Sept. 2019, pp. 386–401, https://doi.org/10.3322/caac.21578.

    Article  Google Scholar 

  40. Zaorsky, Nicholas G., et al. “The Evolution of Brachytherapy for Prostate Cancer.” Nature Reviews Urology, vol. 14, no. 7, 2017, pp. 415–39, https://doi.org/10.1038/nrurol.2017.76.

    Article  PubMed  PubMed Central  Google Scholar 

  41. Davis, Brian J., et al. “American Brachytherapy Society Consensus Guidelines for Transrectal Ultrasound-Guided Permanent Prostate Brachytherapy.” Brachytherapy, vol. 11, no. 1, 2012, pp. 6–19, https://doi.org/10.1016/j.brachy.2011.07.005.

    Article  PubMed  Google Scholar 

  42. King, Martin T., et al. “Low Dose Rate Brachytherapy for Primary Treatment of Localized Prostate Cancer: A Systemic Review and Executive Summary of an Evidence-Based Consensus Statement.” Brachytherapy, vol. 20, no. 6, 2021, pp. 1114–29, https://doi.org/10.1016/j.brachy.2021.07.006.

    Article  PubMed  Google Scholar 

  43. Michalski, Jeff M., et al. “Effect of Brachytherapy With External Beam Radiation Therapy Versus Brachytherapy Alone for Intermediate-Risk Prostate Cancer: NRG Oncology RTOG 0232 Randomized Clinical Trial.” Journal of Clinical Oncology, vol. 41, no. 24, Aug. 2023, pp. 4035–44, https://doi.org/10.1200/JCO.22.01856.

    Article  CAS  PubMed  Google Scholar 

  44. Morris, W. James, et al. “Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-Risk Prostate Cancer.” International Journal of Radiation Oncology, Biology, Physics, vol. 98, no. 2, June 2017, pp. 275–85, https://doi.org/10.1016/j.ijrobp.2016.11.026.

    Article  Google Scholar 

  45. Oh, Justin, et al. “An Updated Analysis of the Survival Endpoints of ASCENDE-RT.” International Journal of Radiation Oncology Biology Physics, vol. 115, no. 5, 2023, pp. 1061–70, https://doi.org/10.1016/j.ijrobp.2022.11.005.

    Article  Google Scholar 

  46. Demanes, D. Jeffrey, and Michel I. Ghilezan. “High-Dose-Rate Brachytherapy as Monotherapy for Prostate Cancer.” Brachytherapy, vol. 13, no. 6, 2014, pp. 529–41, https://doi.org/10.1016/j.brachy.2014.03.002.

    Article  Google Scholar 

  47. Hoskin, Peter J., et al. “Randomised Trial of External-Beam Radiotherapy Alone or with High-Dose-Rate Brachytherapy for Prostate Cancer: Mature 12-Year Results.” Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, vol. 154, Jan. 2021, pp. 214–19, https://doi.org/10.1016/j.radonc.2020.09.047.

    Article  CAS  PubMed  Google Scholar 

  48. Jadvar, Hossein, et al. “Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.” Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine, vol. 63, no. 1, Jan. 2022, pp. 59–68, https://doi.org/10.2967/jnumed.121.263262.

    Article  Google Scholar 

  49. Swanson, Gregory P., et al. “Predominant Treatment Failure in Postprostatectomy Patients Is Local: Analysis of Patterns of Treatment Failure in SWOG 8794.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 25, no. 16, June 2007, pp. 2225–29, https://doi.org/10.1200/JCO.2006.09.6495.

    Article  PubMed  Google Scholar 

  50. Bolla, Michel, et al. “Postoperative Radiotherapy after Radical Prostatectomy: A Randomised Controlled Trial (EORTC Trial 22911).” Lancet (London, England), vol. 366, no. 9485, Aug. 2005, pp. 572–78, https://doi.org/10.1016/S0140-6736(05)67101-2.

    Article  Google Scholar 

  51. Wiegel, Thomas, et al. “Adjuvant Radiotherapy versus Wait-and-See after Radical Prostatectomy: 10-Year Follow-up of the ARO 96-02/AUO AP 09/95 Trial.” European Urology, vol. 66, no. 2, Aug. 2014, pp. 243–50, https://doi.org/10.1016/j.eururo.2014.03.011.

    Article  Google Scholar 

  52. Pisansky TM, Thompson IM, Valicenti RK et al: Adjuvant and salvage radiotherapy after prostatectomy: ASTRO/AUA Guideline amendment 2018e2019. J Urol 2019; 202: 533.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Morgan, Scott C., et al. “Adjuvant Radiotherapy Following Radical Prostatectomy for Pathologic T3 or Margin-Positive Prostate Cancer: A Systematic Review and Meta-Analysis.” Radiotherapy and Oncology: Journal of the European Society for Therapeutic Radiology and Oncology, vol. 88, no. 1, July 2008, pp. 1–9, https://doi.org/10.1016/j.radonc.2008.04.013.

    Article  PubMed  Google Scholar 

  54. Vale, Claire L., et al. “Adjuvant or Early Salvage Radiotherapy for the Treatment of Localised and Locally Advanced Prostate Cancer: A Prospectively Planned Systematic Review and Meta-Analysis of Aggregate Data.” Lancet (London, England), vol. 396, no. 10260, Oct. 2020, pp. 1422–31, https://doi.org/10.1016/S0140-6736(20)31952-8.

    Article  CAS  PubMed  Google Scholar 

  55. Pollack, Alan, et al. “The Addition of Androgen Deprivation Therapy and Pelvic Lymph Node Treatment to Prostate Bed Salvage Radiotherapy (NRG Oncology/RTOG 0534 SPPORT): An International, Multicentre, Randomised Phase 3 Trial.” Lancet (London, England), vol. 399, no. 10338, May 2022, pp. 1886–901, https://doi.org/10.1016/S0140-6736(21)01790-6.

    Article  Google Scholar 

  56. Carrie, Christian, et al. “Salvage Radiotherapy with or without Short-Term Hormone Therapy for Rising Prostate-Specific Antigen Concentration after Radical Prostatectomy (GETUG-AFU 16): A Randomised, Multicentre, Open-Label Phase 3 Trial.” The Lancet. Oncology, vol. 17, no. 6, June 2016, pp. 747–56, https://doi.org/10.1016/S1470-2045(16)00111-X.

    Article  CAS  Google Scholar 

  57. Shipley, William U., et al. “Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.” The New England Journal of Medicine, vol. 376, no. 5, Feb. 2017, pp. 417–28, https://doi.org/10.1056/NEJMoa1607529.

    Article  PubMed  PubMed Central  Google Scholar 

  58. Valle, Luca F., et al. “A Systematic Review and Meta-Analysis of Local Salvage Therapies After Radiotherapy for Prostate Cancer (MASTER).” European Urology, vol. 80, no. 3, Sept. 2021, pp. 280–92, https://doi.org/10.1016/j.eururo.2020.11.010.

    Article  PubMed  Google Scholar 

  59. Ingrosso, Gianluca, et al. “Nonsurgical Salvage Local Therapies for Radiorecurrent Prostate Cancer: A Systematic Review and Meta-Analysis.” European Urology Oncology, vol. 3, no. 2, Apr. 2020, pp. 183–97, https://doi.org/10.1016/j.euo.2018.12.011.

    Article  Google Scholar 

  60. Patel, Krishnan R., et al. “A Phase 1 Trial of Focal Salvage Stereotactic Body Radiation Therapy for Radiorecurrent Prostate Cancer.” Practical Radiation Oncology, vol. 13, no. 6, 2023, pp. 540–50, https://doi.org/10.1016/j.prro.2023.05.012.

    Article  PubMed  Google Scholar 

  61. Fuller, Donald, et al. “Retreatment for Local Recurrence of Prostatic Carcinoma After Prior Therapeutic Irradiation: Efficacy and Toxicity of HDR-Like SBRT.” International Journal of Radiation Oncology, Biology, Physics, vol. 106, no. 2, Feb. 2020, pp. 291–99, https://doi.org/10.1016/j.ijrobp.2019.10.014.

    Article  CAS  Google Scholar 

  62. Crook, Juanita, et al. “Salvage Low-Dose-Rate Prostate Brachytherapy: Clinical Outcomes of a Phase 2 Trial for Local Recurrence after External Beam Radiation Therapy (NRG Oncology/RTOG 0526).” International Journal of Radiation Oncology, Biology, Physics, vol. 112, no. 5, Apr. 2022, pp. 1115–22, https://doi.org/10.1016/j.ijrobp.2021.10.138.

    Article  Google Scholar 

  63. Yamada, Yoshiya, et al. “A Phase II Study of Salvage High-Dose-Rate Brachytherapy for the Treatment of Locally Recurrent Prostate Cancer after Definitive External Beam Radiotherapy.” Brachytherapy, vol. 13, no. 2, 2014, pp. 111–16. https://doi.org/10.1016/j.brachy.2013.11.005.

    Article  Google Scholar 

  64. Supiot, Stéphane, et al. “OLIGOPELVIS GETUG P07, a Multicenter Phase II Trial of Combined High-Dose Salvage Radiotherapy and Hormone Therapy in Oligorecurrent Pelvic Node Relapses in Prostate Cancer.” European Urology, vol. 80, no. 4, 2021, pp. 405–14, https://doi.org/10.1016/j.eururo.2021.06.010.

    Article  CAS  Google Scholar 

  65. Franzese, Ciro, et al. “Assessing the Role of Stereotactic Body Radiation Therapy in a Large Cohort of Patients with Lymph Node Oligometastases: Does It Affect Systemic Treatment’s Intensification?” Radiotherapy and Oncology, vol. 150, 2020, pp. 184–90, https://doi.org/10.1016/j.radonc.2020.06.029.

    Article  CAS  Google Scholar 

  66. Cuccia, Francesco, et al. “Stereotactic Body Radiotherapy for Lymph-Nodal Oligometastatic Prostate Cancer: A Multicenter Retrospective Experience.” Medicina (Kaunas, Lithuania), vol. 59, no. 8, Aug. 2023, p. 1442, https://doi.org/10.3390/medicina59081442.

    Article  Google Scholar 

  67. Zilli, Thomas, et al. “The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer Metastases.” European Urology Focus, vol. 7, no. 2, 2021, pp. 241–44, https://doi.org/10.1016/j.euf.2020.12.010.

    Article  Google Scholar 

  68. Sweeney, Christopher J., et al. “Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.” New England Journal of Medicine, vol. 373, no. 8, Aug. 2015, pp. 737–46, https://doi.org/10.1056/NEJMoa1503747.

    Article  CAS  PubMed  Google Scholar 

  69. Fizazi, Karim, et al. “Abiraterone Acetate plus Prednisone in Patients with Newly Diagnosed High-Risk Metastatic Castration-Sensitive Prostate Cancer (LATITUDE): Final Overall Survival Analysis of a Randomised, Double-Blind, Phase 3 Trial.” The Lancet Oncology, vol. 20, no. 5, 2019, pp. 686–700, https://doi.org/10.1016/S1470-2045(19)30082-8.

    Article  Google Scholar 

  70. Hamid, Anis A., et al. “Metastatic Hormone-Sensitive Prostate Cancer: Toward an Era of Adaptive and Personalized Treatment.” American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting, vol. 43, May 2023, p. e390166, https://doi.org/10.1200/EDBK_390166.

    Article  PubMed  Google Scholar 

  71. Parker, Christopher C., et al. “Radiotherapy to the Primary Tumour for Newly Diagnosed, Metastatic Prostate Cancer (STAMPEDE): A Randomised Controlled Phase 3 Trial.” The Lancet, vol. 392, no. 10162, 2018, pp. 2353–66, https://doi.org/10.1016/S0140-6736(18)32486-3.

    Article  Google Scholar 

  72. Bossi, Alberto, et al. “Prostate Irradiation in Men with de Novo, Low-Volume, Metastatic, Castration-Sensitive Prostate Cancer (MCSPC): Results of PEACE-1, a Phase 3 Randomized Trial with a 2x2 Design.” Journal of Clinical Oncology, vol. 41, no. 17_suppl, June 2023, pp. LBA5000–LBA5000, https://doi.org/10.1200/JCO.2023.41.17_suppl.LBA5000.

    Article  Google Scholar 

  73. SWOG Cancer Research Network. “SWOG 1802: Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer.” ClinicalTrials.Gov ID, 25 Mar. 2024, https://clinicaltrials.gov/study/NCT03678025.

  74. Ost, Piet, et al. “Surveillance or Metastasis-Directed Therapy for Oligometastatic Prostate Cancer Recurrence: A Prospective, Randomized, Multicenter Phase II Trial.” Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology, vol. 36, no. 5, Feb. 2018, pp. 446–53, https://doi.org/10.1200/JCO.2017.75.4853.

    Article  Google Scholar 

  75. Phillips, Ryan, et al. “Outcomes of Observation vs Stereotactic Ablative Radiation for Oligometastatic Prostate Cancer: The ORIOLE Phase 2 Randomized Clinical Trial.” JAMA Oncology, vol. 6, no. 5, May 2020, pp. 650–59, https://doi.org/10.1001/jamaoncol.2020.0147.

    Article  Google Scholar 

  76. Bolla, Michel, et al. “External Irradiation with or without Long-Term Androgen Suppression for Prostate Cancer with High Metastatic Risk: 10-Year Results of an EORTC Randomised Study.” The Lancet. Oncology, vol. 11, no. 11, Nov. 2010, pp. 1066–73, https://doi.org/10.1016/S1470-2045(10)70223-0.

    Article  CAS  Google Scholar 

  77. Kishan, Amar U., et al. “Androgen Deprivation Therapy Use and Duration with Definitive Radiotherapy for Localised Prostate Cancer: An Individual Patient Data Meta-Analysis.” The Lancet Oncology, vol. 23, no. 2, 2022, pp. 304–16, https://doi.org/10.1016/S1470-2045(21)00705-1.

    Article  CAS  PubMed  Google Scholar 

  78. Schmidt-Hegemann, Nina-Sophie, et al. “ESTRO-ACROP Recommendations for Evidence-Based Use of Androgen Deprivation Therapy in Combination with External-Beam Radiotherapy in Prostate Cancer.” Radiotherapy and Oncology, vol. 183, 2023, p. 109544, https://doi.org/10.1016/j.radonc.2023.109544.

    Article  CAS  Google Scholar 

  79. Desai, Kunal, et al. “Hormonal Therapy for Prostate Cancer.” Endocrine Reviews, vol. 42, no. 3, May 2021, pp. 354–73, https://doi.org/10.1210/endrev/bnab002.

    Article  Google Scholar 

  80. NRG-GU011: A Phase II Double-Blinded, Placebo Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean). https://www.nrgoncology.org/Clinical-Trials/Protocol/nrg-gu011?filter=nrg-gu011. Accessed 25 Mar. 2024.

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Washington, Fred Hutchinson Cancer Center, 1959 NE Pacific St, Seattle, WA, 98195, USA

    Sasha Swensen, Jay J. Liao, Jonathan J. Chen, Katherine Kim, Ting Martin Ma & Emily S. Weg

Authors
  1. Sasha Swensen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jay J. Liao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jonathan J. Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Katherine Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ting Martin Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Emily S. Weg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emily S. Weg.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Swensen, S., Liao, J.J., Chen, J.J. et al. The expanding role of radiation oncology across the prostate cancer continuum. Abdom Radiol (2024). https://doi.org/10.1007/s00261-024-04408-3

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00261-024-04408-3

Keywords

Search

Navigation